Don't miss out on the latest business and technology news for chemical engineers, featuring select items in relation to Food, Pharmaceuticals & Bioengineering!
Funding round raises $121M for Recursion Pharmaceuticals
Recursion Pharmaceuticals gained $121 million from a Series C financing round and will use the funds to advance its artificial intelligence-based drug development system to produce cellular images by the millions and use machine-learning software for data analysis to filter through possible therapeutic compounds.
Genentech, Skyhawk partner to develop oncologic, neurological drugs
A collaboration between Skyhawk Therapeutics and Roche subsidiary Genentech will develop RNA-targeting therapies for oncologic and neurological diseases. The only financial disclosure made regarding the deal was that it could total an estimated $2 billion over time.
Corn-based biofuel shown to reduce GHG emissions in two new studies
The Renewable Fuels Association reports that greenhouse gas emissions were shown to be significantly reduced through the use of grain-based biofuel in two studies. Geoff Cooper, president and CEO of the RFA, stated, "As the Environmental Protection Agency (EPA) considers the GHG impacts of expanded ethanol consumption under the Renewable Fuel Standard, we urge them to strongly consider the latest science and data regarding ethanol's tremendous carbon benefits."
Startup harnesses microbes to make new protein product
A Finnish company is gearing up to market a new protein product made by combining hydrogen, carbon dioxide and a nutrients solution that is fed to microbes. Solein, as the protein has been dubbed by its creators, will probably be sold first as a liquid protein source but could eventually be used in meat alternatives.
Moleculin unveils data on annamycin trial for relapsed, refractory AML
Moleculin Biotech announced that dosing for its Phase I/II study being conducted in Poland to assess the efficacy of annamycin in relapsed or refractory acute myeloid leukemia will advance to the next dose level of 180 mg/m2 since no adverse events related to the drug were experienced by participants who received the lower dose of 150 mg/m2. A parallel study is also being conducted by Moleculin in the US.
Drugmakers ask FDA to expand sources of RWD, RWE
Gilead and Novartis asked the FDA to consider more sources of real-world data and expand the scope of allowable real-world evidence in regulatory decisions. Novartis says pharmacy claims should be considered as RWE, and Gilead says data from lab tests, expanded access protocols and health care delivery should be allowable sources of RWD.
Administration committed to making drug importation plan work, Azar says
A year after calling drug importation a "gimmick," HHS Secretary Alex Azar said he and President Donald Trump are now committed to making importation of cheaper drugs from other countries work. The administration's change in stance offers hope to states that seek to import drugs from Canada to address rising prescription drug costs.
Enrollment to start first in vivo gene therapy study for blindness
Enrollment has commenced for the very first in human trials to test a gene therapy that will be assessed as a treatment for people with Leber congenital amaurosis, a form of blindness that's inherited. Editas Medicine and Allergan will enroll 18 persons from all over the US starting this fall.
- Log in to post comments